Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Azilect Market Report 2017 - Research and Markets

Research and Markets
Posted on: 08 Nov 17

The "Azilect" report has been added to Research and Markets' offering.

Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine oxidase inhibitor to enter the market. Azilect prolongs the activity of dopamine in the brain to restore a measure of normal locomotion, gait, and coordination. Rasagiline is believed to be five to 10 times more potent at inhibiting the monoamine oxidase B enzyme than selegiline. In contrast to selegiline, Azilect has a cleaner side-effect profile as it does not metabolize into amphetamine derivatives.

Analyst Outlook

Sales for Teva's monoamine oxidase B (MAO-B) inhibitor Azilect (rasagiline) continue to build momentum, with approvals across all Parkinson's disease severities. Although the much-touted neuroprotective indication for Azilect was rejected by the US Food and Drug Administration (FDA) in 2012, line and geographic expansions will propel the drug towards market leadership until genericization and pipeline candidates such as Newron Pharmaceuticals' Xadago (safinamide) begin to erode Azilect's patient share. Teva has noted that the 11% increase in global revenues of Azilect to $549m in 2014 was due to increased prices and demand for the drug in the US and EU.

Key Topics Covered:

1 Product Profiles

2 Azilect: Parkinson's disease

List of Figures

Figure 1: Azilect (rasagiline; Teva/Lundbeck/Takeda) SWOT analysis in Parkinson's disease

Figure 2: Drug assessment summary for Azilect in Parkinson's disease

Figure 3: Drug assessment summary for Azilect in Parkinson's disease

List of Tables

Table 1: Azilect (rasagiline; Teva/Lundbeck/Takeda) - drug profile

Table 2: Pivotal Phase III clinical trial data for Azilect (rasagiline; Teva/Lundbeck/Takeda) in Parkinson's disease

For more information about this report visit https://www.researchandmarkets.com/research/d3smnw/azilect.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108006016/en/

Business Wire
www.businesswire.com

Last updated on: 08/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.